A 52-Week Efficacy and Safety Study of Teneligliptin, as an Add-On to Empagliflozin and Metformin in Patients With Type 2 Diabetes Mellitus: A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial (TERA305 Study)

Diabetes, Obesity & Metabolism

The paper

Jun Sung Moon, Kyung Ah Han, Dong‐Lim Kim,

Sang Yong Kim, Soo‐Kyung Kim, Bon Jeong Ku, Woo Je Lee, Tae Keun Oh, Ji A Seo, Sang‐Ah Chang, Moon-Kyu Lee, Kyu Jeung Ahn, Chul Sik Kim, Tae Nyun Kim,

Bong Soo

Yeungnam University Medical Center · Yonsei University

Diabetes, Obesity & Metabolism · 5 Oct 2026

doi.org/10.1111/dom.71315 PubMed 42832816

Retatrutide reduces bodyweight in obesity and type 2 diabetes
Lancet · 4 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
Diabetes, Obesity & Metabolism · 4 Oct 2026

A 52-Week Efficacy and Safety Study of Teneligliptin, as an Add-On to Empagliflozin and Metformin in Patients With Type 2 Diabetes Mellitus: A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial (TERA305 Study)

The paper

Related